Eli Lilly - The third textbook swingtrade!💊Eli Lilly ( NYSE:LLY ) is again retesting the previous highs:
🔎Analysis summary:
Back in 2012, Eli Lilly broke out of a major bullish flag consolidation. And during the subsequent uptrend, Eli Lilly provided innumerable textbook swingtrading setups. Right now, Eli Lilly is just once again cr
Compare with Eli Lilly and Company
29.47 USD
20.64 B USD
65.18 B USD
848.42 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
IPO date
Jul 9, 1970
ISIN
US5324571083
CUSIP
532457108
FIGI
BBG000BNBDC2
Identifiers
ISIN US5324571083
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.
Eli Lilly and Company — Sell Side | 1,098Eli Lilly and Company is developing a bearish setup, with the current price structure pointing toward a potential decline to the 1,098 level. The recent configuration suggests that upside momentum is losing strength, creating room for sellers to push the stock into lower territory.
The setup indica
Eli Lilly (LLY): Bullish Setup at Key SupportLLY is showing bullish strength off a key support area that previously acted as a strong resistance zone.
Eli Lilly & Co. is a $1.12 trillion market-cap pharmaceutical company engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Its portfolio spans diabetes, onco
Is Eli Lilly Pulling Back Into a Possible Area of Value?Weekly Support Back in Play
After reaching a fresh all-time high at $1,292.65, Eli Lilly has pulled back into the important weekly support zone around $1,100. This is an area we highlighted back in July as one to watch on any meaningful pullback.
Primary Trend Remains Strong
Price remains comfor
ELI LILLY Final macro correction before a $1700 rally in 2027.Almost 6 months ago (March 10, see chart below), we gave a strong Sell Signal on Eli Lilly (LLY) while it was marginally above $1000, targeting $850:
The price reacted immediately, hitting along with our Target, the 1W MA100 (red trend-line). It naturally rebounded (to last month's All Time Hig
$LLY: Here’s why I’m short and what I think is likely next.📉 NYSE:LLY : Here’s why I’m short and what I think is likely next.
The chart structure has turned bearish, and today’s selling adds further confirmation.
In this video, I explain the setup, why I took the short, and what I’m watching next. 👇
NYSE:LLY #EliLilly #Stocks #StockMarket #Trading #Te
LLY Signals Potential Buying OpportunityLLY is seeing renewed buying interest after retracing to its 20-day and 50-day moving averages. The stock remains in an uptrend, making higher highs and higher lows while trading above both moving averages, signaling continued bullish momentum.
Eli Lilly & Co. is a $1.18 trillion market-cap pharmac
Another Weak LLY - Eli Lilly Still Hasn't Broken This StuctureGood afternoon, Traders.
I'm taking yet another look at Eli Lilly and it's looking like Deja Vu all over again. One of the biggest lessons I try to enforce is that **market structure isn't isolated to one timeframe.** Institutions leave footprints on one timeframe, then often repeat that same be
LLY: Stock Approaches Major Resistance ZoneEli Lilly (NYSE:LLY) trades near $1,215 per share, holding a market cap above $1.1 trillion. Recent momentum is driven by strong Q2 2026 earnings, raised full-year guidance to $86 billion in revenue, and U.K regulatory approval for its oral weight loss pill, Foundayo, intensifying competition in the
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateAug 14, 2064
Coupon5.20% (Fixed)
Maturity dateFeb 27, 2063
Coupon4.95% (Fixed)
Maturity dateOct 15, 2065
Coupon5.65% (Fixed)
Maturity dateMar 15, 2059
Coupon4.15% (Fixed)
Maturity dateFeb 9, 2064
Coupon5.10% (Fixed)
Maturity dateFeb 12, 2065
Coupon5.60% (Fixed)
Maturity dateMay 20, 2066
Coupon5.70% (Fixed)
Maturity dateSep 14, 2043
Coupon1.63% (Fixed)
Maturity dateMar 15, 2049
Coupon3.95% (Fixed)
Maturity dateAug 14, 2054
Coupon5.05% (Fixed)
Maturity dateFeb 12, 2055
Coupon5.50% (Fixed)
See all LLY bonds
Frequently asked questions
The current price of LLY is 1,179.27 USD — it has increased by 0.83% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Eli Lilly and Company stocks are traded under the ticker LLY.
LLY stock has risen by 2.21% compared to the previous week, the month change is a 4.58% rise, over the last year Eli Lilly and Company has showed a 38.46% increase.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLY price has a max estimate of 1,680.00 USD and a min estimate of 930.00 USD. Watch LLY chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLY stock is 2.44% volatile and has beta coefficient of 0.09. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of 1.11 T, it has increased by 0.04% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
LLY earnings for the last quarter are 8.38 USD per share, whereas the estimation was 6.40 USD resulting in a 30.92% surprise. The estimated earnings for the next quarter are 9.92 USD per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to 22.97 B USD, despite the estimated figure of 20.82 B USD. In the next quarter, revenue is expected to reach 22.29 B USD.
LLY net income for the last quarter is 7.09 B USD, while the quarter before that showed 7.40 B USD of net income which accounts for 0.00% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.73 USD. As of today, Dividend Yield (TTM)% is 0.57%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.56% in 2025, and payout ratio reached 26.14%. The year before the numbers were 0.67% and 44.39% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 11, 2026, the company has 50 K employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is 41.71 B USD, and current EBITDA margin is 48.62%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the buy signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.









